accounttight focus on CE ANDA and 505(b)(2) trials has been embraced by the Generic and Specialty Pharmaceuticals Industry,' added Dr. Thomas Ichim, bioRASI's Chief Scientific Officer. 'Sponsors welcome our ever-growing expertise in optimizing CE trial...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to bioRASI to Exhibit at the 2009 AAPS Annual Meeting in Los Angeles, CA
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
